跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
李 欣學
Doctor
內科部
電子郵件
cleanylee
gmail
com
h-index
181
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2018
2024
每年研究成果
概覽
指紋
網路
研究成果
(24)
類似的個人檔案
(6)
指紋
查看啟用 Sin-Syue Li 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
National Cohort Study
50%
Maternal Survival
50%
RHOA G17V
50%
Pregnancy-associated Cancer
50%
Gemtuzumab Ozogamicin
50%
Treatment Outcome
50%
High-risk Acute Leukemia
50%
Pomalidomide
50%
Cancer Therapeutics-related Cardiac Dysfunction
50%
Multiple Myeloma Patients
50%
Post-transplant Outcomes
50%
PLASMIC Score
50%
T Cell Purification
50%
Daratumumab
50%
Transplant Registry
50%
Risk Prediction Score
50%
Lipid Profiling
50%
Aplastic Anemia
50%
Letermovir
50%
Antigen Sensitivity
50%
Idiopathic Pneumonia Syndrome
50%
Hepatic Veno-occlusive Disease
50%
Population Database
50%
Candour
50%
Thymectomy
43%
Cytomegalovirus Prophylaxis
33%
ADAMTS13
31%
Hyper-CVAD
21%
Chimeric Antigen Receptor T-cell Therapy
21%
Symptomatic Relapse
18%
ADAMTS13 Protein
18%
Good's Syndrome
18%
Hyper-CVAD Regimen
14%
Asia
12%
Taiwan
12%
Immunosuppressive Therapy
12%
Severe Aplastic Anemia
12%
National Health Insurance Research Database (NHIRD)
12%
Hematopoietic Stem Cell Transplantation
12%
Bone Marrow Failure
12%
Androgens
12%
Patient Size
10%
Allogeneic Hematopoietic Cell Transplant Recipients
10%
B-stage
8%
Myeloma Therapy
8%
Plasma Triglyceride Concentration
8%
Triglyceride Hydrolysis
8%
Transplantation Autologous
8%
Subcutaneous Panniculitis-like T-cell Lymphoma (SPTCL)
8%
High-dose Cytarabine
7%
Immunology and Microbiology
Hematopoietic Stem Cell Transplantation
100%
Chimeric Antigen Receptor T-Cell
100%
Chimeric Antigen Receptor
58%
Human immunodeficiency virus
50%
Human Herpesvirus 8
50%
Serine
50%
Lenalidomide
50%
Autologous Stem Cell Transplantation
50%
Myeloid
50%
Organ Transplantation
50%
Lymphoproliferative Disorders
50%
Lipid Blood Level
50%
Chimeric Antigen Receptor T-Cell Therapy
37%
High-Density Lipoprotein
33%
Low-Density Lipoprotein
25%
Cholesterol Blood Level
25%
Blood Plasma
25%
Lipoprotein
16%
Embase
16%
Autoimmune Hemolytic Anemia
16%
Triacylglycerol Blood Level
16%
Human Immunodeficiency Virus Infection
12%
Immunodeficiency
12%
Allogeneic Stem Cell Transplantation
12%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Anti-Thymocyte Globulin
10%
Mortality Rate
10%
Genetic Screening
8%
Density Gradient
8%
Apolipoprotein
8%
Lipid Homeostasis
8%
Cell Viability
7%
Carcinoembryonic Antigen
7%
Cytokine Release
7%
Tumor Cell
7%
T Cell Activation
7%
T Cell
7%
Cytotoxicity
7%
Antigen Specificity
7%
Magnetic-Activated Cell Sorting
7%
Peptides
7%
Therapeutic Research
5%
Conditioning
5%
Autologous Hematopoietic Stem Cell Transplantation
5%
Medicine and Dentistry
Lenalidomide
50%
Von Willebrand Factor Cleaving Proteinase
50%
Cancer Therapy
50%
Bone Marrow Transplantation
50%
Letermovir
50%
Human immunodeficiency virus
50%
Idiopathic Pneumonia Syndrome
50%
Organ Transplantation
50%
Aplastic Anemia
50%
Human Herpesvirus 8
50%
Inotuzumab Ozogamicin
50%
Posttransplant Lymphoproliferative Disease
50%
Primary Effusion Lymphoma
50%
Daratumumab
50%
Chimeric Antigen Receptor
37%
Chimeric Antigen Receptor T-Cell Immunotherapy
37%
Hematopoietic Cell
35%
First Year Postpartum
20%
Cancer Treatment
16%
Scoring System
15%
Receptor Sensitivity
12%
T Cell Exhaustion
12%
Philadelphia 1 Chromosome
10%
Androgen
10%
Bone Marrow Failure
10%
Hematopoietic Stem Cell Transplantation
10%
Immunosuppressive Treatment
10%
Risk Stratification
10%
Patient with Transplantation
10%
Genetic Screening
8%
Comorbidity Assessment
8%
Organ Toxicity
7%
Differential Diagnosis
6%
Immune Deficiency
6%
Clinician
6%
Intermediate Risk Population
6%
Effusion
6%
Non-Hodgkin Lymphoma
6%
Human Immunodeficiency Virus Infection
6%
Heart Left Ventricle Failure
5%
Cardiopulmonary Exercise Test
5%
Congestive Heart Failure
5%
Oxygen Consumption
5%
All Cause Mortality
5%
Hazard Ratio
5%
Left Ventricular Systolic Dysfunction
5%
High Risk Population
5%
Thymocyte Antibody
5%
Multivariate Analysis
5%
Rare Disease
5%
